

TDS/# 6 8.21.02/645 Patent 270/070US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PHS

In re the Application of:) Group Art Unit: 1645
Langenfeld, John	Examiner: Not Yet Assigned RECEIVED
Serial No.: 10/044,716	HEULIVES
Filed: January 11, 2000	JUL 1 1 2002
For: BONE MORPHOGENETIC PROTEIN-2 IN THE TREATMENT AND DIAGNOSIS OF CANCER	TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application

LA-240675.1					
CERTIFICATE OF MA	AILING				
(37 C.F.R. §1.8a)				
I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.					
·	Lena Dishakjian				
•	Name of Person Mailing Paper				
June 28, 2002 Date of Deposit	Signature of Person Mailing Paper-0				

filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

> However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR §1.17(p) to the deposit account referenced below.

The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Lyon & Lyon's Deposit Account No. 12-2475.

> Respectfully submitted, LYON & LYON LLP

Dated: 6/28/02

By:

Michael J. Wise Reg. No. 34,047

22249

LYON & LYON LLP 633 W. Fifth Street, **Suite 4700** Los Angeles, CA 90071

FORM PT	0-144				ATTY. DOC 272/070US	NO.	SERIAL NO). 944,716	
LIST OF PATENTS AND OTHER ITEMS OF PINFORMATION DISCLOSURE S Use several sheets if necessity		S FOR APPLICANT'S STATEMENT		APPLICANT:	·	nfeld, John			
				FILING DATE: 01/11/02		GROUP: 1645			
JUL 0 5	2002								
EXAMINET	LA PA CER		U.S. I	PATENT DOCU	MENTS				
EXAMINET INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUB CLASS		ING ATE
·	AA								
	AB						REC	EIV	ED
	AC						JUL	1 1 20	002
	AD								
	AE						TECH CE	MIEK II	000/290
	AF								
	AG								
	АН								
		Ţ	FOREIG	N PATENT DO	CUMENTS			TOANG	ATTON
EXAMINER INITIAL	ļ	DOCUMENT NUMBER	DATE	С	OUNTRY	CLASS	SUB CLASS	YES	LATION NO
	AI	·							
	AJ					•			
	AK								
	NC	N PATENT LITERATURE	DOCUMENT	'S (Including A	author, Title, Date, F	ertinent I	Pages, etc.)		
	Abe et al., "Essential Requirement of BMPs-2/4 for Both Osteoblast and Osteoclast Formation in Murine Bone Marrow Cultures from Adult Mice: Antagonism by Noggin," J. of Bone and Mineral Res., Vol. 15, No. 4, (2000)								
	AL	pp. 663-673							`
	AM	An et al., "Recombinant Rat that Supports the Gro							in the
	AN	Celeste et al., "Identificate Purified From Bovine Bo	tion of Transi	forming Growth	Factor β Family Mer	nbers Pres	ent in Bone-Ir	ductive	Protein
	Au	Cui et al., "BMP-4 is Pro						Developr	nent,"

	EXAMINER:	DATE CONSIDERED:
	Not Yet Assigned	
- 4		

The EMBO Journal. Vol. 17, No. 16, (1998), pp.4735-4743

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

FORM PTO-1449			ATTY. DOC	NO.	SERIAL N	-	1
		100	272/070US		10,	/044,716	
LIST OF PATENTS AND OTHER ITE	MS FOR APPLIX	AMS E	APPLICANT:			RECEIV	EL
INFORMATION DISCLOSU	RE STATEMENT		\sim	Langenf	eld, John		
	1	0 5 2002	FAING DATE:		GROUP:	1 2	002
(Use several sheets if	necessary)	JUL 0 2 2	01/11/02		1645	JUL 1 1 4	Olor

•		
		Cunnigham et al., "Osteogenin and Recommentation Morphogenetic Protein 2B are Chemotacine (1) On the H 1800/2.
		Monocytes and Stimulate Transforming Growth Factor B1 mRNA Expression, Proc. Natl. Acad. Sci. USA, vol.
	AP	89, (1992), pp. 11740-11744
		Erickson et al., "Recombinant Bone Morphogenetic Protein (BMP)-2 Regulates Costochondral Growth Plate
		Chondrocytes and Induces Expression of BMP-2 and BMP-4 in a Cell Maturation-Dependent Manner," J. of
	AQ	Orthopaedic Research, Vol. 15, (1997) pp. 371-380
		Liu et al., "Human Type II Receptor for Bone Morphogenic Proteins (BMPs): Extension of the Two-Kinase
	AR	Receptor Model to the BMPs." Molecular and Cellular Biology, Vol. 15, No. 7, (1995), pp. 3479-3486
		Sakou et al., "Localization of Smads, the TGF-β Family Intracellular Signaling Components During Endochondral
ĺ	AS	Ossification," J. of Bone and Mineral Res., Vol. 14, No. 7, (1999), pp. 1145-1152
		ten Dijke et al., "Identification of Type I Receptors for Osteogenic Protein-1 and Bone Morphogenetic Protein-4,"
	AT	J. of Bio. Chem., Vol. 269, No. 25, (1994), pp. 16985-16988
		Vainio et al., "Identification of BMP-4 as a Signal Mediating Secondary Induction Between Epithelial and
	AU	Mesenchymal Tissues During Early Tooth Developmental," Cell, Vol. 75, 1993, pp. 45-48
		Warburton et al., "The Molecular Basis of Lung Morphogenesis," Mechanism of Development, Vol. 92, (2000),
1	AV	pp. 55-81
		Weaver et al., "BMP Signaling Regulates Proximal-Distal Differentiation of Endotherm in Mouse Lung
	AW	Development," Development, Vol. 126 (1999), pp. 4005-4015
		Willette et al., "BMP-2 Gene Expression and Effects on Human Vascular Smooth Muscle Cells," J. of Vascular
	AX	Research, Vol. 36, (1999), pp. 120-125
		Wozney et al., "Novel Regulators of Bone Formation: Molecular Clones and Activities," Science, Vol. 242,
	AY	(1988), pp. 1528-1534

EXAMINER:	DATE CONSIDERED:	
Not Yet Assigned		
	the MDED CO	<u></u>

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

Information Disclosure Statement – Section 9 PTO-1449